Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal



Page Path
HOME > Search
6 "PPAR alpha"
Article category
Publication year
Funded articles
Article image
New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins
Kyuho Kim, Henry N. Ginsberg, Sung Hee Choi
Diabetes Metab J. 2022;46(4):517-532.   Published online July 27, 2022
Correction in: Diabetes Metab J 2022;46(5):817
  • 11,509 View
  • 901 Download
  • 30 Web of Science
  • 32 Crossref
AbstractAbstract PDFPubReader   ePub   
Statins are the cornerstone of the prevention and treatment of atherosclerotic cardiovascular disease (ASCVD). However, even under optimal statin therapy, a significant residual ASCVD risk remains. Therefore, there has been an unmet clinical need for novel lipid-lowering agents that can target low-density lipoprotein cholesterol (LDL-C) and other atherogenic particles. During the past decade, several drugs have been developed for the treatment of dyslipidemia. Inclisiran, a small interfering RNA that targets proprotein convertase subtilisin/kexin type 9 (PCSK9), shows comparable effects to that of PCSK9 monoclonal antibodies. Bempedoic acid, an ATP citrate lyase inhibitor, is a valuable treatment option for the patients with statin intolerance. Pemafibrate, the first selective peroxisome proliferator-activated receptor alpha modulator, showed a favorable benefit-risk balance in phase 2 trial, but the large clinical phase 3 trial (PROMINENT) was recently stopped for futility based on a late interim analysis. High dose icosapent ethyl, a modified eicosapentaenoic acid preparation, shows cardiovascular benefits. Evinacumab, an angiopoietin-like 3 (ANGPTL3) monoclonal antibody, reduces plasma LDL-C levels in patients with refractory hypercholesterolemia. Novel antisense oligonucleotides targeting apolipoprotein C3 (apoC3), ANGPTL3, and lipoprotein(a) have significantly attenuated the levels of their target molecules with beneficial effects on associated dyslipidemias. Apolipoprotein A1 (apoA1) is considered as a potential treatment to exploit the athero-protective effects of high-density lipoprotein cholesterol (HDL-C), but solid clinical evidence is necessary. In this review, we discuss the mode of action and clinical outcomes of these novel lipid-lowering agents beyond statins.


Citations to this article as recorded by  
  • The role of adherence in patients with chronic diseases
    Michel Burnier
    European Journal of Internal Medicine.2024; 119: 1.     CrossRef
  • Bempedoic acid: new evidence and recommendations on use
    Kristina Paponja, Ivan Pećin, Željko Reiner, Maciej Banach
    Current Opinion in Lipidology.2024; 35(1): 41.     CrossRef
  • Genetic insights into repurposing statins for hyperthyroidism prevention: a drug-target Mendelian randomization study
    Anqi Huang, Xinyi Wu, Jiaqi Lin, Chiju Wei, Wencan Xu
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • Targeting host-specific metabolic pathways—opportunities and challenges for anti-infective therapy
    Monika I. Konaklieva, Balbina J. Plotkin
    Frontiers in Molecular Biosciences.2024;[Epub]     CrossRef
  • Neutrophil Extracellular Traps (NETs) and Atherosclerosis: Does Hypolipidemic Treatment Have an Effect?
    Petros Adamidis, Despoina Pantazi, Iraklis Moschonas, Evangelos Liberopoulos, Alexandros Tselepis
    Journal of Cardiovascular Development and Disease.2024; 11(3): 72.     CrossRef
  • Modulating effects of crocin on lipids and lipoproteins: Mechanisms and potential benefits
    Habib Yaribeygi, Mina Maleki, Farin Rashid-Farrokhi, Payman Raise Abdullahi, Mohammad Amin Hemmati, Tannaz Jamialahmadi, Amirhossein Sahebkar
    Heliyon.2024; 10(7): e28837.     CrossRef
  • Assessing the Benefits of Lifestyle Influences on Cardiovascu-lar Health After Acute Coronary Syndrome
    Marius Rus, Claudia Elena Stanis, Paula Marian, Lilliana Oana Pobirci, Loredana Ioana Banszki, Veronica Huplea, Gheorghe Adrian Osiceanu, Bianca-Maria Pop, Gabriela Dogaru, Felicia Liana Andronie-Cioara
    Balneo and PRM Research Journal.2024; 15(Vol.15, no): 660.     CrossRef
  • ​Comprehensive mendelian randomization analysis of plasma proteomics to identify new therapeutic targets for the treatment of coronary heart disease and myocardial infarction
    Ziyi Sun, Zhangjun Yun, Jianguo Lin, Xiaoning Sun, Qingqing Wang, Jinlong Duan, Cheng Li, Xiaoxiao Zhang, Siyu Xu, Zeqi Wang, Xingjiang Xiong, Kuiwu Yao
    Journal of Translational Medicine.2024;[Epub]     CrossRef
  • Hypercholesterolemia: a literature review on management using tafolecimab: a novel member of PCSK9 monoclonal antibodies
    Zaheer Qureshi, Mikail Khanzada, Adnan Safi, Eeshal Fatima, Faryal Altaf, Timothy J. Vittorio
    Annals of Medicine & Surgery.2024; 86(5): 2818.     CrossRef
  • Therapeutic approach in the treatment of dyslipidemia: Novelties and challenges
    Katarina Lalić, Nataša Rajković, Ljiljana Popović, Sandra Singh-Lukač, Iva Rasulić, Ana Petakov, Milica Krstić, Marija Mitrović
    Galenika Medical Journal.2024; 3(9): 31.     CrossRef
  • Lipid Variability Induces Endothelial Dysfunction by Increasing Inflammation and Oxidative Stress
    Marie Rhee, Joonyub Lee, Eun Young Lee, Kun-Ho Yoon, Seung-Hwan Lee
    Endocrinology and Metabolism.2024; 39(3): 511.     CrossRef
  • Exploring the Perceptions and Behaviours of UK Prescribers Concerning Novel Lipid-Lowering Agent Prescriptions: A Qualitative Study
    Sarah Baig, Shahrauz Mughal, Yousuf Murad, Mandeep Virdee, Zahraa Jalal
    Pharmacy.2024; 12(4): 104.     CrossRef
  • Need of education and training of healthcare professionals on the PCSK9 inhibitors in cardiovascular disease
    Jan Schjøtt, Kristine Heitmann
    European Journal of Cardiovascular Nursing.2024;[Epub]     CrossRef
  • CXCL9, IL2RB, and SPP1, potential diagnostic biomarkers in the co-morbidity pattern of atherosclerosis and non-alcoholic steatohepatitis
    Xize Wu, Changbin Yuan, Jiaxiang Pan, Yi Zhou, Xue Pan, Jian Kang, Lihong Ren, Lihong Gong, Yue Li
    Scientific Reports.2024;[Epub]     CrossRef
  • Liver cancer cells as the model for developing liver-targeted RNAi therapeutics
    Beibei Hou, Linhui Qin, Linfeng Huang
    Biochemical and Biophysical Research Communications.2023; 644: 85.     CrossRef
  • Insights into Causal Cardiovascular Risk Factors from Mendelian Randomization
    C. M. Schooling, J. V. Zhao
    Current Cardiology Reports.2023; 25(2): 67.     CrossRef
  • Secoisolariciresinol diglucoside and anethole ameliorate lipid abnormalities, oxidative injury, hypercholesterolemia, heart, and liver conditions
    Sana Noreen, Habib‐ur Rehman, Tabussam Tufail, Huma Badar Ul Ain, Chinaza Godswill Awuchi
    Food Science & Nutrition.2023; 11(6): 2620.     CrossRef
  • Colesterol remanente, riesgo vascular y prevención de la arteriosclerosis
    Xavier Pintó, Marta Fanlo, Virginia Esteve, Jesús Millán, Agustín Blanco, Mariano Blasco, José Luís Díaz Díaz, Ángel Díaz Rodríguez, Alipio Mangas, Vicente Pascual, Juan Pedro Botet, Pablo Pérez Martínez
    Clínica e Investigación en Arteriosclerosis.2023; 35(4): 206.     CrossRef
  • Evolving Management of Low‐Density Lipoprotein Cholesterol: A Personalized Approach to Preventing Atherosclerotic Cardiovascular Disease Across the Risk Continuum
    Michael J. Wilkinson, Norman E. Lepor, Erin D. Michos
    Journal of the American Heart Association.2023;[Epub]     CrossRef
  • The cell origins of foam cell and lipid metabolism regulated by mechanical stress in atherosclerosis
    Zhi Ouyang, Jian Zhong, Junyi Shen, Ye Zeng
    Frontiers in Physiology.2023;[Epub]     CrossRef
  • Triglyceride-Rich Lipoprotein Metabolism: Key Regulators of Their Flux
    Alejandro Gugliucci
    Journal of Clinical Medicine.2023; 12(13): 4399.     CrossRef
  • Remnant cholesterol, vascular risk, and prevention of atherosclerosis
    Xavier Pintó, Marta Fanlo, Virginia Esteve, Jesús Millán
    Clínica e Investigación en Arteriosclerosis (English Edition).2023; 35(4): 206.     CrossRef
  • Antibiotics and Lipid-Modifying Agents: Potential Drug–Drug Interactions and Their Clinical Implications
    Marios Spanakis, Danny Alon-Ellenbogen, Petros Ioannou, Nikolaos Spernovasilis
    Pharmacy.2023; 11(4): 130.     CrossRef
  • Advances in Treatment of Dyslipidemia
    Jill Dybiec, Wiktoria Baran, Bartłomiej Dąbek, Piotr Fularski, Ewelina Młynarska, Ewa Radzioch, Jacek Rysz, Beata Franczyk
    International Journal of Molecular Sciences.2023; 24(17): 13288.     CrossRef
  • Peroxisome Proliferator-Activated Receptor α in Lipoprotein Metabolism and Atherosclerotic Cardiovascular Disease
    Elena Valeria Fuior, Evangelia Zvintzou, Theodosios Filippatos, Katerina Giannatou, Victoria Mparnia, Maya Simionescu, Anca Violeta Gafencu, Kyriakos E. Kypreos
    Biomedicines.2023; 11(10): 2696.     CrossRef
  • Preparation, characterization and in vivo pharmacokinetic study of ginsenoside Rb1-PLGA nanoparticles
    Lixin Du, Huiling Lu, Yifei Xiao, Zhihua Guo, Ya Li
    Scientific Reports.2023;[Epub]     CrossRef
  • Dysregulation of Cholesterol Homeostasis in Ovarian Cancer
    Zahraa Qusairy, Anne Gangloff, Shuk On Annie Leung
    Current Oncology.2023; 30(9): 8386.     CrossRef
  • Riesgo residual. Conclusiones
    Ángel Cequier, José Luis Zamorano
    Revista Española de Cardiología Suplementos.2023; 23: 25.     CrossRef
  • Causal effects of circulating lipids and lipid-lowering drugs on the risk of urinary stones: a Mendelian randomization study
    Zilong Tan, Jing Hong, Aochuan Sun, Mengdi Ding, Jianwu Shen
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Bibliometric analysis of residual cardiovascular risk: trends and frontiers
    Lin Wang, Sutong Wang, Chaoyuan Song, Yiding Yu, Yuehua Jiang, Yongcheng Wang, Xiao Li
    Journal of Health, Population and Nutrition.2023;[Epub]     CrossRef
  • Current Understanding on the Genetic Basis of Key Metabolic Disorders: A Review
    Kenneth Francis Rodrigues, Wilson Thau Lym Yong, Md. Safiul Alam Bhuiyan, Shafiquzzaman Siddiquee, Muhammad Dawood Shah, Balu Alagar Venmathi Maran
    Biology.2022; 11(9): 1308.     CrossRef
  • Lipoprotein Lipase: Is It a Magic Target for the Treatment of Hypertriglyceridemia
    Joon Ho Moon, Kyuho Kim, Sung Hee Choi
    Endocrinology and Metabolism.2022; 37(4): 575.     CrossRef
Original Article
Basic Research
Peroxisomal Fitness: A Potential Protective Mechanism of Fenofibrate against High Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Mice
Songling Jiang, Md Jamal Uddin, Xiaoying Yu, Lingjuan Piao, Debra Dorotea, Goo Taeg Oh, Hunjoo Ha
Diabetes Metab J. 2022;46(6):829-842.   Published online June 24, 2022
  • 5,537 View
  • 300 Download
  • 7 Web of Science
  • 6 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Non-alcoholic fatty liver disease (NAFLD) has been increasing in association with the epidemic of obesity and diabetes. Peroxisomes are single membrane-enclosed organelles that play a role in the metabolism of lipid and reactive oxygen species. The present study examined the role of peroxisomes in high-fat diet (HFD)-induced NAFLD using fenofibrate, a peroxisome proliferator-activated receptor α (PPARα) agonist.
Eight-week-old male C57BL/6J mice were fed either a normal diet or HFD for 12 weeks, and fenofibrate (50 mg/kg/day) was orally administered along with the initiation of HFD.
HFD-induced liver injury as measured by increased alanine aminotransferase, inflammation, oxidative stress, and lipid accumulation was effectively prevented by fenofibrate. Fenofibrate significantly increased the expression of peroxisomal genes and proteins involved in peroxisomal biogenesis and function. HFD-induced attenuation of peroxisomal fatty acid oxidation was also significantly restored by fenofibrate, demonstrating the functional significance of peroxisomal fatty acid oxidation. In Ppara deficient mice, fenofibrate failed to maintain peroxisomal biogenesis and function in HFD-induced liver injury.
The present data highlight the importance of PPARα-mediated peroxisomal fitness in the protective effect of fenofibrate against NAFLD.


Citations to this article as recorded by  
  • Pharmacological potential of ginseng and ginsenosides in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
    Young-Su Yi
    Journal of Ginseng Research.2024; 48(2): 122.     CrossRef
  • Fenofibrate alleviates NAFLD by enhancing the PPARα/PGC-1α signaling pathway coupling mitochondrial function
    Xuemei Wang, Jieying Wang, Cao Ying, Yuan Xing, Xuan Su, Ke Men
    BMC Pharmacology and Toxicology.2024;[Epub]     CrossRef
  • Role of Fenofibrate Use in Dyslipidemia and Related Comorbidities in the Asian Population: A Narrative Review
    Chaicharn Deerochanawong, Sin Gon Kim, Yu-Cheng Chang
    Diabetes & Metabolism Journal.2024; 48(2): 184.     CrossRef
  • Current Therapeutical Approaches Targeting Lipid Metabolism in NAFLD
    Manuela Vitulo, Elisa Gnodi, Giulia Rosini, Raffaella Meneveri, Roberto Giovannoni, Donatella Barisani
    International Journal of Molecular Sciences.2023; 24(16): 12748.     CrossRef
  • PPARα agonist fenofibrate prevents postoperative cognitive dysfunction by enhancing fatty acid oxidation in mice
    Tiantian Liu, Xinlu Chen, Ziqi Wei, Xue Han, Yujia Liu, Zhengliang Ma, Tianjiao Xia, Xiaoping Gu
    Translational Neuroscience.2023;[Epub]     CrossRef
  • Fenofibrate enhances lipid deposition via modulating PPARγ, SREBP-1c, and gut microbiota in ob/ob mice fed a high-fat diet
    Ying Zhang, Xiu-Bin Jia, Yun-Chao Liu, Wen-Qian Yu, Yan-Hong Si, Shou-Dong Guo
    Frontiers in Nutrition.2022;[Epub]     CrossRef
Fibrates Revisited: Potential Role in Cardiovascular Risk Reduction
Nam Hoon Kim, Sin Gon Kim
Diabetes Metab J. 2020;44(2):213-221.   Published online April 23, 2020
  • 8,321 View
  • 332 Download
  • 45 Web of Science
  • 47 Crossref
AbstractAbstract PDFPubReader   

Fibrates, peroxisome proliferator-activated receptor-α agonists, are potent lipid-modifying drugs. Their main effects are reduction of triglycerides and increase in high-density lipoprotein levels. Several randomized controlled trials have not demonstrated their benefits on cardiovascular risk reduction, especially as an “add on” to statin therapy. However, subsequent analyses by major clinical trials, meta-analyses, and real-world evidence have proposed their potential in specific patient populations with atherogenic dyslipidemia and metabolic syndrome. Here, we have reviewed and discussed the accumulated data on fibrates to understand their current status in cardiovascular risk management.


Citations to this article as recorded by  
  • Associations of omega-3 fatty acids vs. fenofibrate with adverse cardiovascular outcomes in people with metabolic syndrome: propensity matched cohort study
    Nam Hoon Kim, Ji Yoon Kim, Jimi Choi, Sin Gon Kim
    European Heart Journal - Cardiovascular Pharmacotherapy.2024; 10(2): 118.     CrossRef
  • Role of PPARα in inflammatory response of C2C12 myotubes
    Yuki Shimizu, Keiko Hamada, Tingting Guo, Chie Hasegawa, Yusuke Kuga, Katsushi Takeda, Takashi Yagi, Hiroyuki Koyama, Hiroshi Takagi, Daisuke Aotani, Hiromi Kataoka, Tomohiro Tanaka
    Biochemical and Biophysical Research Communications.2024; 694: 149413.     CrossRef
  • Obicetrapib: Reversing the Tide of CETP Inhibitor Disappointments
    John J. P. Kastelein, Andrew Hsieh, Mary R. Dicklin, Marc Ditmarsch, Michael H. Davidson
    Current Atherosclerosis Reports.2024; 26(2): 35.     CrossRef
  • Metabolic Flexibility of the Heart: The Role of Fatty Acid Metabolism in Health, Heart Failure, and Cardiometabolic Diseases
    Virginia Actis Dato, Stephan Lange, Yoshitake Cho
    International Journal of Molecular Sciences.2024; 25(2): 1211.     CrossRef
  • ApoB100 and Atherosclerosis: What’s New in the 21st Century?
    Dimitris Kounatidis, Natalia G. Vallianou, Aikaterini Poulaki, Angelos Evangelopoulos, Fotis Panagopoulos, Theodora Stratigou, Eleni Geladari, Irene Karampela, Maria Dalamaga
    Metabolites.2024; 14(2): 123.     CrossRef
  • Follistatin-like 1 (FSTL1) levels as potential early biomarker of cardiovascular disease in a Mexican population
    N. Ponce-Ruíz, J. F. Herrera-Moreno, A. E. Rojas-García, B. S. Barrón-Vivanco, C. A. González-Arias, Y. Y. Bernal-Hernández, L. Ortega-Cervantes, J. Ponce-Gallegos, J. A. Hernández-Nolasco, I. M. Medina-Díaz
    Heart and Vessels.2024; 39(6): 563.     CrossRef
  • Role of Fenofibrate Use in Dyslipidemia and Related Comorbidities in the Asian Population: A Narrative Review
    Chaicharn Deerochanawong, Sin Gon Kim, Yu-Cheng Chang
    Diabetes & Metabolism Journal.2024; 48(2): 184.     CrossRef
  • Coenzyme Q10 in atherosclerosis
    Minjun Liao, Xueke He, Yangyang Zhou, Weiqiang Peng, Xiao-Mei Zhao, Miao Jiang
    European Journal of Pharmacology.2024; 970: 176481.     CrossRef
  • Onion Polyphenols as Multi-Target-Directed Ligands in MASLD: A Preliminary Molecular Docking Study
    Maria Rosaria Paravati, Anna Caterina Procopio, Maja Milanović, Giuseppe Guido Maria Scarlata, Nataša Milošević, Maja Ružić, Nataša Milić, Ludovico Abenavoli
    Nutrients.2024; 16(8): 1226.     CrossRef
  • Therapeutic approach in the treatment of dyslipidemia: Novelties and challenges
    Katarina Lalić, Nataša Rajković, Ljiljana Popović, Sandra Singh-Lukač, Iva Rasulić, Ana Petakov, Milica Krstić, Marija Mitrović
    Galenika Medical Journal.2024; 3(9): 31.     CrossRef
  • Research trends in lipid-lowering therapies for coronary heart disease combined with hyperlipidemia: a bibliometric study and visual analysis
    Quankai Cheng, Jingjing Sun, Haicheng Zhong, Ziming Wang, Chang Liu, Sheng Zhou, Jie Deng
    Frontiers in Pharmacology.2024;[Epub]     CrossRef
  • Expression of FAM159B in Humans, Rats, and Mice: A Cross-species Examination
    Anna-Sophia Liselott Beyer, Daniel Kaemmerer, Jörg Sänger, Amelie Lupp
    Journal of Histochemistry & Cytochemistry.2024;[Epub]     CrossRef
  • The Pleiotropic Effects of Lipid-Modifying Interventions: Exploring Traditional and Emerging Hypolipidemic Therapies
    Dimitris Kounatidis, Nikolaos Tentolouris, Natalia G. Vallianou, Iordanis Mourouzis, Irene Karampela, Theodora Stratigou, Eleni Rebelos, Marina Kouveletsou, Vasileios Stamatopoulos, Eleni Tsaroucha, Maria Dalamaga
    Metabolites.2024; 14(7): 388.     CrossRef
  • Fenofibrate’s impact on cardiovascular risk in patients with diabetes: a nationwide propensity-score matched cohort study
    Sangmo Hong, Kyung-Soo Kim, Kyungdo Han, Cheol-Young Park
    Cardiovascular Diabetology.2024;[Epub]     CrossRef
  • Present and Future of Dyslipidaemia Treatment—A Review
    Iveta Merćep, Andro Vujević, Dominik Strikić, Ivana Radman, Ivan Pećin, Željko Reiner
    Journal of Clinical Medicine.2023; 12(18): 5839.     CrossRef
  • VLDL receptor gene therapy for reducing atherogenic lipoproteins
    Ronald M. Krauss, Jonathan T. Lu, Joseph J. Higgins, Cathryn M. Clary, Ray Tabibiazar
    Molecular Metabolism.2023; 69: 101685.     CrossRef
  • The emerging role of PPAR-alpha in breast cancer
    Zhiwen Qian, Lingyan Chen, Jiayu Liu, Ying Jiang, Yan Zhang
    Biomedicine & Pharmacotherapy.2023; 161: 114420.     CrossRef
  • Molecular mechanisms and therapeutic perspectives of peroxisome proliferator‐activated receptor α agonists in cardiovascular health and disease
    Yujie Pu, Chak Kwong Cheng, Hongsong Zhang, Jiang‐Yun Luo, Li Wang, Brian Tomlinson, Yu Huang
    Medicinal Research Reviews.2023; 43(6): 2086.     CrossRef
  • Macrophage angiotensin-converting enzyme reduces atherosclerosis by increasing peroxisome proliferator-activated receptor α and fundamentally changing lipid metabolism
    DuoYao Cao, Zakir Khan, Xiaomo Li, Suguru Saito, Ellen A Bernstein, Aaron R Victor, Faizan Ahmed, Aoi O Hoshi, Luciana C Veiras, Tomohiro Shibata, Mingtian Che, Lei Cai, Ryan E Temel, Jorge F Giani, Daniel J Luthringer, Ajit S Divakaruni, Derick Okwan-Duo
    Cardiovascular Research.2023; 119(9): 1825.     CrossRef
  • Rapid flow synthesis of fenofibrate via scalable flash chemistry with in-line Li recovery
    Sanket A. Kawale, Dong-Chang Kang, Gwang-Noh Ahn, Amirreza Mottafegh, Ji-Ho Kang, Gi-Su Na, Dong-Pyo Kim
    Chemical Engineering Journal.2023; 477: 147033.     CrossRef
  • Effectiveness and Safety of Fenofibrate in Routine Treatment of Patients with Hypertriglyceridemia and Metabolic Syndrome
    Marat V. Ezhov, Gregory P. Arutyunov
    Diseases.2023; 11(4): 140.     CrossRef
  • Development of New Genome Editing Tools for the Treatment of Hyperlipidemia
    Giulio Preta
    Cells.2023; 12(20): 2466.     CrossRef
  • Exploring the hypolipidemic effects of bergenin from Saxifraga melanocentra Franch: mechanistic insights and potential for hyperlipidemia treatment
    Li Zhang, Yingying Tong, Yan Fang, Jinjin Pei, Qilan Wang, Gang Li
    Lipids in Health and Disease.2023;[Epub]     CrossRef
  • Obesity and Dyslipidemia
    Barbora Nussbaumerova, Hana Rosolova
    Current Atherosclerosis Reports.2023; 25(12): 947.     CrossRef
  • Bibliometric analysis of residual cardiovascular risk: trends and frontiers
    Lin Wang, Sutong Wang, Chaoyuan Song, Yiding Yu, Yuehua Jiang, Yongcheng Wang, Xiao Li
    Journal of Health, Population and Nutrition.2023;[Epub]     CrossRef
  • Hypertriglyceridemia in Apoa5–/– mice results from reduced amounts of lipoprotein lipase in the capillary lumen
    Ye Yang, Anne P. Beigneux, Wenxin Song, Le Phuong Nguyen, Hyesoo Jung, Yiping Tu, Thomas A. Weston, Caitlyn M. Tran, Katherine Xie, Rachel G. Yu, Anh P. Tran, Kazuya Miyashita, Katsuyuki Nakajima, Masami Murakami, Yan Q. Chen, Eugene Y. Zhen, Joonyoung R.
    Journal of Clinical Investigation.2023;[Epub]     CrossRef
  • Blood-Derived Lipid and Metabolite Biomarkers in Cardiovascular Research from Clinical Studies: A Recent Update
    Dipali Kale, Amol Fatangare, Prasad Phapale, Albert Sickmann
    Cells.2023; 12(24): 2796.     CrossRef
  • Effective, disease-modifying, clinical approaches to patients with mild-to-moderate hypertriglyceridaemia
    Gary F Lewis, Robert A Hegele
    The Lancet Diabetes & Endocrinology.2022; 10(2): 142.     CrossRef
  • Effects of Alirocumab on Triglyceride Metabolism: A Fat-Tolerance Test and Nuclear Magnetic Resonance Spectroscopy Study
    Thomas Metzner, Deborah R. Leitner, Karin Mellitzer, Andrea Beck, Harald Sourij, Tatjana Stojakovic, Gernot Reishofer, Winfried März, Ulf Landmesser, Hubert Scharnagl, Hermann Toplak, Günther Silbernagel
    Biomedicines.2022; 10(1): 193.     CrossRef
  • Is there a role of lipid-lowering therapies in the management of fatty liver disease?
    Ismini Tzanaki, Aris P Agouridis, Michael S Kostapanos
    World Journal of Hepatology.2022; 14(1): 119.     CrossRef
  • Therapeutic Strategies and Chemoprevention of Atherosclerosis: What Do We Know and Where Do We Go?
    Ana Clara Aprotosoaie, Alexandru-Dan Costache, Irina-Iuliana Costache
    Pharmaceutics.2022; 14(4): 722.     CrossRef
  • The Overlooked Transformation Mechanisms of VLCFAs: Peroxisomal β-Oxidation
    Qinyue Lu, Weicheng Zong, Mingyixing Zhang, Zhi Chen, Zhangping Yang
    Agriculture.2022; 12(7): 947.     CrossRef
  • Current Trends of Big Data Research Using the Korean National Health Information Database
    Mee Kyoung Kim, Kyungdo Han, Seung-Hwan Lee
    Diabetes & Metabolism Journal.2022; 46(4): 552.     CrossRef
  • New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins
    Kyuho Kim, Henry N. Ginsberg, Sung Hee Choi
    Diabetes & Metabolism Journal.2022; 46(4): 517.     CrossRef
  • Novel Targets for a Combination of Mechanical Unloading with Pharmacotherapy in Advanced Heart Failure
    Agata Jedrzejewska, Alicja Braczko, Ada Kawecka, Marcin Hellmann, Piotr Siondalski, Ewa Slominska, Barbara Kutryb-Zajac, Magdi H. Yacoub, Ryszard T. Smolenski
    International Journal of Molecular Sciences.2022; 23(17): 9886.     CrossRef
  • Lipoprotein Lipase: Is It a Magic Target for the Treatment of Hypertriglyceridemia
    Joon Ho Moon, Kyuho Kim, Sung Hee Choi
    Endocrinology and Metabolism.2022; 37(4): 575.     CrossRef
  • Fenofibrate add-on to statin treatment is associated with low all-cause death and cardiovascular disease in the general population with high triglyceride levels
    Kyung-Soo Kim, Sangmo Hong, Kyungdo Han, Cheol-Young Park
    Metabolism.2022; 137: 155327.     CrossRef
  • Alterations of HDL’s to piHDL’s Proteome in Patients with Chronic Inflammatory Diseases, and HDL-Targeted Therapies
    Veronika Vyletelová, Mária Nováková, Ľudmila Pašková
    Pharmaceuticals.2022; 15(10): 1278.     CrossRef
  • Cardiovascular Risk Profile and Lipid Management in the Population-Based Cohort Study LATINO: 20 Years of Real-World Data
    Cristina Gavina, Daniel Seabra Carvalho, Marisa Pardal, Marta Afonso-Silva, Diana Grangeia, Ricardo Jorge Dinis-Oliveira, Francisco Araújo, Tiago Taveira-Gomes
    Journal of Clinical Medicine.2022; 11(22): 6825.     CrossRef
  • New and Emerging lipid-lowering Therapy
    James M Backes, Daniel E Hilleman
    Future Cardiology.2021; 17(8): 1407.     CrossRef
  • Systemic PFOS and PFOA exposure and disturbed lipid homeostasis in humans: what do we know and what not?
    Styliani Fragki, Hubert Dirven, Tony Fletcher, Bettina Grasl-Kraupp, Kristine Bjerve Gützkow, Ron Hoogenboom, Sander Kersten, Birgitte Lindeman, Jochem Louisse, Ad Peijnenburg, Aldert H. Piersma, Hans M. G. Princen, Maria Uhl, Joost Westerhout, Marco J. Z
    Critical Reviews in Toxicology.2021; 51(2): 141.     CrossRef
  • A network pharmacology analysis on drug‐like compounds from Ganoderma lucidum for alleviation of atherosclerosis
    Ki Kwang Oh, Md. Adnan, Dong Ha Cho
    Journal of Food Biochemistry.2021;[Epub]     CrossRef
  • Efficacy and Safety of Fenofibrate-Statin Combination Therapy in Patients With Inadequately Controlled Triglyceride Levels Despite Previous Statin Monotherapy: A Multicenter, Randomized, Double-blind, Phase IV Study
    Myung Soo Park, Jong-Chan Youn, Eung Ju Kim, Ki Hoon Han, Sang Hak Lee, Sung Hea Kim, Byung Jin Kim, Sung Uk Kwon, Kyu-Hyung Ryu
    Clinical Therapeutics.2021; 43(10): 1735.     CrossRef
  • Prevalence of and Factors Associated With the Prescription of Fibrates Among Patients Receiving Lipid-Lowering Drugs in Germany
    Louis Jacob, Roger-Axel Greiner, Mark Luedde, Karel Kostev
    Journal of Cardiovascular Pharmacology.2021; 78(6): 885.     CrossRef
  • Challenging Issues in the Management of Cardiovascular Risk Factors in Diabetes During the COVID-19 Pandemic: A Review of Current Literature
    Leili Rahimi, Mojtaba Malek, Faramarz Ismail-Beigi, Mohammad E. Khamseh
    Advances in Therapy.2020; 37(8): 3450.     CrossRef
  • Treatment With Gemfibrozil Prevents the Progression of Chronic Kidney Disease in Obese Dahl Salt-Sensitive Rats
    Corbin A. Shields, Bibek Poudel, Kasi C. McPherson, Andrea K. Brown, Ubong S. Ekperikpe, Evan Browning, Lamari Sutton, Denise C. Cornelius, Jan M. Williams
    Frontiers in Physiology.2020;[Epub]     CrossRef
  • Oxidative Stress and Inflammation in Renal and Cardiovascular Complications of Diabetes
    Amelia Charlton, Jessica Garzarella, Karin A. M. Jandeleit-Dahm, Jay C. Jha
    Biology.2020; 10(1): 18.     CrossRef
Role of Peroxisome Proliferator-Activated Receptor α in Diabetic Nephropathy
Sungjin Chung, Cheol Whee Park
Diabetes Metab J. 2011;35(4):327-336.   Published online August 31, 2011
  • 65,535 View
  • 47 Download
  • 17 Crossref
AbstractAbstract PDFPubReader   

With a developing worldwide epidemic of diabetes mellitus, the renal complications associated with diabetes have become a serious health concern. Primary therapy for treating diabetic nephropathy is a multifactorial process. Peroxisome proliferator-activated receptor alpha (PPARα) agonists have been used primarily in clinical practice for the treatment of dyslipidemia and insulin resistance. Given that PPARα expression and regulation of metabolic pathways are involved in oxidative stress, inflammation, blood pressure regulation, and the renin-angiotensin aldosterone system, PPARα likely influences the development and pathogenesis of diabetic nephropathy via indirect effects on glucose and lipid homeostasis and also by direct action on the kidneys. These findings suggest that PPARα may become an important therapeutic target for treating diabetic renal complications.


Citations to this article as recorded by  
  • Oxidative stress, inflammation, and steatosis elucidate the complex dynamics of HgCl2 induced liver damage in Channa punctata
    Shefalee Singh, Shikha Dwivedi, Adeel Ahmad Khan, Anamika Jain, Shraddha Dwivedi, Kamlesh Kumar Yadav, Indrani Dubey, Abha Trivedi, Sunil P. Trivedi, Manoj Kumar
    Scientific Reports.2024;[Epub]     CrossRef
  • The Proteome of Circulating Large Extracellular Vesicles in Diabetes and Hypertension
    Akram Abolbaghaei, Maddison Turner, Jean-François Thibodeau, Chet E. Holterman, Christopher R. J. Kennedy, Dylan Burger
    International Journal of Molecular Sciences.2023; 24(5): 4930.     CrossRef
  • Metformin mitigates renal dysfunction in obese insulin-resistant rats via activation of the AMPK/PPARα pathway
    Laongdao Thongnak, Nattavadee Pengrattanachot, Sasivimon Promsan, Nichakorn Phengpol, Prempree Sutthasupha, Krit Jaikumkao, Anusorn Lungkaphin
    Archives of Pharmacal Research.2023; 46(5): 408.     CrossRef
  • A comprehensive insight into the molecular and cellular mechanisms of the effects of Propolis on preserving renal function: a systematic review
    Paniz Anvarifard, Maryam Anbari, Alireza Ostadrahimi, Mohammadreza Ardalan, Zohreh Ghoreishi
    Nutrition & Metabolism.2022;[Epub]     CrossRef
  • APX-115, a pan-NADPH oxidase inhibitor, protects development of diabetic nephropathy in podocyte specific NOX5 transgenic mice
    Eun Soo Lee, Hong Min Kim, Sun Hee Lee, Kyung Bong Ha, Yoon Soo Bae, Soo Jin Lee, Sung Hwan Moon, Eun Young Lee, Ji-Hye Lee, Choon Hee Chung
    Free Radical Biology and Medicine.2020; 161: 92.     CrossRef
  • Fenofibrate decreased microalbuminuria in the type 2 diabetes patients with hypertriglyceridemia
    Xiaomeng Sun, Jia Liu, Guang Wang
    Lipids in Health and Disease.2020;[Epub]     CrossRef
  • AMPK allostery: A therapeutic target for the management/treatment of diabetic nephropathy
    Kehinde Sulaimon Ayinde, Olamide Tosin Olaoba, Boyenle Ibrahim, Du Lei, Qian Lu, Xiaoxing Yin, Temitope Isaac Adelusi
    Life Sciences.2020; 261: 118455.     CrossRef
  • Greater efficacy of atorvastatin versus a non-statin lipid-lowering agent against renal injury: potential role as a histone deacetylase inhibitor
    Ravi Shankar Singh, Dharmendra Kumar Chaudhary, Aradhana Mohan, Praveen Kumar, Chandra Prakash Chaturvedi, Carolyn M. Ecelbarger, Madan M. Godbole, Swasti Tiwari
    Scientific Reports.2016;[Epub]     CrossRef
  • Upregulation of SIRT1-AMPK by thymoquinone in hepatic stellate cells ameliorates liver injury
    Yong Yang, Ting Bai, You-Li Yao, De-Quan Zhang, Yan-Ling Wu, Li-Hua Lian, Ji-Xing Nan
    Toxicology Letters.2016; 262: 80.     CrossRef
  • Peroxisome proliferator-activated receptor α-dependent renoprotection of murine kidney by irbesartan
    Makoto Harada, Yuji Kamijo, Takero Nakajima, Koji Hashimoto, Yosuke Yamada, Hisashi Shimojo, Frank J. Gonzalez, Toshifumi Aoyama
    Clinical Science.2016; 130(21): 1969.     CrossRef
  • Anthocyanin-rich Seoritae extract ameliorates renal lipotoxicity via activation of AMP-activated protein kinase in diabetic mice
    Eun Sil Koh, Ji Hee Lim, Min Young Kim, Sungjin Chung, Seok Joon Shin, Bum Soon Choi, Hye Won Kim, Seong Yeon Hwang, Sae Woong Kim, Cheol Whee Park, Yoon Sik Chang
    Journal of Translational Medicine.2015;[Epub]     CrossRef
  • Diabetic Kidney Disease: From Epidemiology to Clinical Perspectives
    Cheol Whee Park
    Diabetes & Metabolism Journal.2014; 38(4): 252.     CrossRef
  • Peroxisome proliferator-activated receptor agonists in a battle against the aging kidney
    Marijn M. Speeckaert, Céline Vanfraechem, Reinhart Speeckaert, Joris R. Delanghe
    Ageing Research Reviews.2014; 14: 1.     CrossRef
  • Fenofibrate and dipyridamole treatments in low-doses either alone or in combination blunted the development of nephropathy in diabetic rats
    Pitchai Balakumar, Rajavel Varatharajan, Ying Hui Nyo, Raja Renushia, Devarajan Raaginey, Ann Nah Oh, Shaikh Sohrab Akhtar, Mani Rupeshkumar, Karupiah Sundram, Sokkalingam A. Dhanaraj
    Pharmacological Research.2014; 90: 36.     CrossRef
  • Differential effects of low-dose fenofibrate treatment in diabetic rats with early onset nephropathy and established nephropathy
    Supriya Kadian, Nanjaian Mahadevan, Pitchai Balakumar
    European Journal of Pharmacology.2013; 698(1-3): 388.     CrossRef
  • Age-Associated Molecular Changes in the Kidney in Aged Mice
    Ji Hee Lim, Eun Nim Kim, Min Young Kim, Sungjin Chung, Seok Joon Shin, Hyung Wook Kim, Chul Woo Yang, Yong-Soo Kim, Yoon Sik Chang, Cheol Whee Park, Bum Soon Choi
    Oxidative Medicine and Cellular Longevity.2012; 2012: 1.     CrossRef
  • Epidemiology of Obesity, the Metabolic Syndrome, and Chronic Kidney Disease
    Rikki M. Tanner, Todd M. Brown, Paul Muntner
    Current Hypertension Reports.2012; 14(2): 152.     CrossRef
Original Articles
Prevention of Diabetes by Fenofibrate in OLETF Rats: Hepatic Mechanism for Reducing Visceral Adiposity.
Hye Jeong Lee, Mi Kyoung Park, Kyung Il Lee, Young Jun An, Ji Min Kim, Ja Young Park, Young Han, Sook Hee Hong, Sun Seob Choi, Young Hyun Yoo, Joon Duk Suh, Duk Kyu Kim
Korean Diabetes J. 2007;31(1):63-74.   Published online January 1, 2007
  • 2,245 View
  • 19 Download
  • 4 Crossref
AbstractAbstract PDF
The aim of this study is to evaluate the hepatic mechanism of fenofibrate that has the diabetes protective action in rats. METHODS: We chose OLETF rats and divided them into three groups. Fenofibrate (DF) group was fed with diet and fenofibrate (300 mg/kg/day). Paired feeding (Dd) group and free diet (DD) group were fed with diet. After 36 weeks of treatment, all the rats were sacrificed. RESULTS: The fasting blood glucose level of DF group (8.5 +/- 0.9 mmol/L) showed normal. The fasting blood glucose level of Dd group (22.4 +/- 3.0 mmol/L) and DD group (16.9 +/- 3.7 mmol/L) showed significantly increased than that of DF group (P < 0.01, respectively). The body weight, visceral adipose tissue and subcutaneous adipose tissue of DF group were significantly decreased compared to those of Dd and DD groups (P < 0.01, P < 0.05, P < 0.05). DF group showed significantly increased state-3 respiration rate, ATP synthetic activity, state-4 respiration rate and their blood beta-keton body levels than those of control groups (P < 0.01, respectively). DF group showed normal morphology of hepatocytes but DD and Dd groups showed hepatic steatosis with mitochondrial swellings. CONCLUSION: Chronic fenofibrate treatment prevents the development of diabetes in OLETF rats with inhibiting gain of body weight and abdominal adiposity. The hepatic mechanism for reducing visceral adiposity is that fenofibrate leads to increasing oxidative phosphorylation, uncoupling and ketogenesis as well as increasing beta-oxidation of fatty acids. Moreover, fenofibrate treatment prevents the development of hepatic steatosis.


Citations to this article as recorded by  
  • The Differences of Metabolic Syndrome Risk Factors according to Obesity and Abdominal Obesity in Elderly Korean Women
    Kyung-A Shin
    The Korean Journal of Clinical Laboratory Science.2016; 48(4): 304.     CrossRef
  • Effects of Soybean and DJI Chungkukjang Powder on Blood Glucose and Serum Lipid Reduction in db/db Mice
    Jae-Joon Lee, Ah-Ra Kim, Hae-Choon Chang, Hae-Ok Jung, Myung-Yul Lee
    Journal of the Korean Society of Food Science and Nutrition.2012; 41(8): 1086.     CrossRef
  • Comparative analysis of fat and muscle proteins in fenofibratefed type II diabetic OLETF rats: the fenofibrate-dependent expression of PEBP or C11orf59 protein
    Jong-Ryeal Hahm, Jin-Sook Ahn, Hae-Sook Noh, Seon-Mi Baek, Ji-Hye Ha, Tae-Sik Jung, Yong-Jun An, Duk-Kyu Kim, Deok-Ryong Kim
    BMB Reports .2010; 43(5): 337.     CrossRef
  • Comparative analysis of fat and muscle proteins in fenofibratefed type II diabetic OLETF rats: the fenofibrate-dependent expression of PEBP or C11orf59 protein
    Jong-Ryeal Hahm, Jin-Sook Ahn, Hae-Sook Noh, Seon-Mi Baek, Ji-Hye Ha, Tae-Sik Jung, Yong-Jun An, Duk-Kyu Kim, Deok-Ryong Kim
    BMB Reports.2010; 43(5): 337.     CrossRef
Exercise and Fenofibrate Reduces Body Adiposity Synergistically in OLETF Rats.
Young Jun An, Hre Jeong Lee, Mi Kyoung Park, Kyung Il Lee, In Young Koh, Dong Sik Jung, Ah Young Kang, Duk Kyu Kim
Korean Diabetes J. 2004;28(2):131-138.   Published online April 1, 2004
  • 990 View
  • 16 Download
AbstractAbstract PDF
The PPAR alpha activator, Fenofibrate, is a pharmacological ligand, which induces beta-oxidation of long chain fatty acids in the mitochondria of hepatocytes. The beta-oxidation induced by exogenous PPAR alpha activators may be operated maximally when the sustained production of energy substrate in the liver is required by working muscles due to continued exercise. The aim of this study was to determine whether the combination therapy of exercise and Fenofibrate could synergistically reduce body adiposity in OLETF rats. METHODS: Twenty-eight male OLETF rats(13 wk old) were divided into four groups. The diet(n=7) and exercise groups(n=7) were fed with chow for 12 weeks. The Fenofibrate(n=7) and combined treatment(exercise and Fenofibrate) groups (n=7) were fed with Fenofibrate(32mg/kg/day) mixed chow for 12 weeks. The animals in the exercise and combined treatment groups were exercised by running on a treadmill for 12 weeks. At 24 weeks of age, all the rats were sacrificed, and examined by biochemical tests and had their adipose tissue weight measured. RESULTS: There were no significant changes in the retroperitoneal and subcutaneous fats between the diet and Fenofibrate groups, but there were between the diet and combined treatment groups(P<0.05). CONCLUSION: Exercise combined with Fenofibrate synergistically reduces body adiposity in OLETF rats

Diabetes Metab J : Diabetes & Metabolism Journal
Close layer